Technical Data Sheet and Product Science File Launch Readiness

Aditya Raj Singh[1], Ayan Neogi[2], Md Quamruz Zafar[3]
[1,2,3]*Clinivance Labs*

***Abstract*— the goal of this project is to guarantee quality, compliance, and launch readiness by creating and regulating Technical Data Sheets (TDS) and Product Science Files (PSF). It emphasizes organized, digital documentation that supported by cooperation across functional boundaries. In pharmaceutical development, early document integration enhances accuracy of data, compliance with regulations, and overall product lifecycle efficiency.**

Keywords*— *Product Science File (PSF), Pharmaceutical Quality System (PQS), Quality Assurance (QA), Quality by Design (QbD), Technical Data Sheet (TDS

MODULE 1: INTRODUCTION TO LAUNCH READINESS

1.1 What is Launch Readiness?

When a pharmaceutical product is ready to hit the market after a period of development, research, and regulatory approvals, it is said to be a launch ready. A successful launch requires more than just finishing clinical trials and gaining regulatory approval; it also requires being certain that every step of manufacturing, labeling, compliance, and scientific documentation are in line.

To put it simply, launch readiness assures that the medicine is scientifically and practically capable to be deliver to patients safely and effectively, in accordance with regulations, and is validate by scientific evidence.

1.2 Why is Launch Readiness Important?

- Patients Safety: Drugs must be use after efficacy, safety, and quality have been examine and confirmed.
- Regulatory Compliance: authorities such as the FDA (USA), EMA (Europe), and CDSCO (India) require complete and accurate documentation.
- Market Success: A failed launch may result in rejection, recalls, or delays. Patient and healthcare provider trust is increase by a well-planned launch.
- Cross Departmental: Launch readiness unifies marketing, quality assurance, regulatory affairs, and research and development into a single, coordinated effort. [1]

1.3 Key Components of Launch Readiness

- Regulatory Documentation & Records: Generating essential paperwork that support the product's safety, quality, and efficacy profile, such as the Technical Data Sheet (TDS) and Product Science File (PSF).
- Quality System: Ensuring compliance to pharmacopoeial criteria (IP, USP, BP, and EP), Good Manufacturing Practices (GMP), and Good Documentation Practices (GDP).
- Risk Management: Identifying and solving risks like missing information, irregular manufacturing, or incomplete specifications.
- Planning and Schedules: Careful planning is essential for ensuring launch readiness in order to fulfill submission deadlines and prevent approval delays. [2]

1.4 Documentation Role in Launch Readiness

The core of launch readiness is scientific documentation, above all other things. There are two important documents:

- Technical Data Sheet (TDS): TDS gives minimal details about the product, which includes its formulation, testing processes and quality specifications.
- Product Science File (PSF): A comprehensive report that provides the scientific explanations, the data from preclinical and clinical trials, and the reasons for making the product.

Both documents show that the product fulfil the needs of patients and the guidelines set by the government. [3]

1.5 Challenges in Launch Readiness

- Last-minute errors in Technical Data Sheet or Product Science File data.

- Incompatible specifications in different regions of the world.
- The regulatory teams and the manufacturing units are not working together.
- Delays because the dossier fails to be complete.

1.6 Module 1 (Checklist)

✓ Understand what launch readiness is.
✓ Obtain knowledge of the role of records & documentation (TDS & PSF).
✓ Make a note of the quality and regulatory requirements.
✓ Highlight everyday launch readiness risks and challenges.

➢ GUIDELINES

- ICH Q8 (R2): Pharmaceutical Development.
- ICH Q10: Pharmaceutical Quality System.
- ICH M4: Common Technical Document (CTD) for the Registration of Pharmaceuticals.
- WHO Technical Report Series (TRS 1033, Annex 2): Guidance on Good Data and Record Management Practices.
- Indian Pharmacopoeia (latest edition, 2022).
- United States Pharmacopeia (USP 46 – NF 41, 20

MODULE 2: DEFINITION AND SCOPE OF TECHNICAL DATA SHEET (TDS)

2.1 Introduction

In the pharmaceutical industry, the Technical Data Sheet (TDS) acts as one of the most vital scientific and regulatory documents. It provides as a concise and consistent overview of all product-relevant technical data, such as formulation, specifications, analytical techniques, and stability specifications. The TDS focus on the specific, useful information needed for production, evaluation, and regulatory approval, as opposed to huge dossiers that cover several scientific subjects.

2.2 Definition of TDS

Technical Data Sheet is defined as:
"A structured technical document prepared according with regulatory and pharmacopoeial standards that summarizes the vital specifications, testing procedures, manufacturing specifications, conditions of storage, and overall quality characteristics of a pharmaceutical product."

2.3 Scope of TDS in pharmaceuticals

Table No 1: TDS in pharmaceuticals

S.no	Area	Description
1	Regulatory Submissions	A section of regulatory paperwork and approvals
2	Manufacturing	A manual for successful product production.
3	QA & QC	Provides precise release limits, methods, and tests.
4	Technology Transfer	Ensures that everything runs smoothly from research and development to production.
5	Pharmacopoeial Compliance	Demonstrates conformity to EP, BP, USP, and IP
6	Market Readiness	Verifies the product's efficacy, safety, and quality prior to launch.[4]

2.4 Key Components of TDS

Table No 2: TDS Includes

S.no	Component	Description
1	Product Identification	Name, strength, dosage, and therapeutic class.
2	Composition	List of excipients and APIs with quantities.
3	Specifications	Quality characteristics like dissolution, impurities, and assay
4	Analytical Methods	Method validation (UV, HPLC and dissolution)
5	Packaging Information	Compatibility, labeling and container closure systems.
6	Storage and Stability	Recommended humidity, temperature and stability study or data.
7	Regulatory References	Monographs and ICH guidelines.[5]

2.5 Importance of TDS in Launch Readiness

- Functions as a Compliance Tool: regulatory bodies expect organized technical data.

- Error Risk Is Decrease: Explicit specifications help to avoid errors.
- Facilitates Quicker Approvals: Fast delivery of crucial data to regulators.
- Enhances Cross-Functional Coordination: Serves as a resource for manufacturing, QA, QC, and R&D.
- PSF Foundation: TDS provides the key technical data that PSF relies on. [6]

2.6 Challenges in Preparing TDS

- Gaps in Data: Incomplete information or missing data.
- Modifying Specifications: Updates from pharmacopoeias or agencies.
- Global Variations: Every country has different requirements.
- Inconsistencies: Limit, unit, or drafting errors are examples of inconsistencies.

2.7 The Best Methods for Preparing TDS

1. Assess the most recent pharmacopoeial standards (BP, EP, USP, and IP).
2. For data structuring, adhere to ICH guidelines (Q6A, Q8).
3. Maintain the conciseness and clarity.
4. Assure coordination among the regulatory, formulation, and analytical teams.
5. Utilize version control to monitor changes. [7,8]

2.8 Module 2 (Checklist)

- ✓ Define Technical Data Sheet (TDS).
- ✓ Listed Scope of TDS.
- ✓ Listed Key Components o TDS.
- ✓ Overview the Importance of TDS.
- ✓ Identify TDS preparation Challenges.
- ✓ Best Practices to avoid errors.

➢ GUIDELINES

- ICH Q6A: Specifications – Test Procedures and Acceptance Criteria.
- ICH Q8 (R2): Pharmaceutical Development.
- WHO TRS 992: Guidance on Pharmaceutical Development.
- Indian Pharmacopoeia, 2022.
- USP 46 – NF 41, 2023.
- EMA Guideline on Specifications: Test Procedures and Acceptance Criteria.
- FDA Guidance: Quality Considerations for Generic Drug Development.

MODULE 3: DEFINITION AND SCOPE OF PRODUCT SCIENCE FILE (PSF)

3.1 Introduction

All the necessary technical, scientific, and regulatory information for a pharmaceutical product have collected in the Product Science File (PSF), a comprehensive internal document. The PSF provides complete justifications and clarifications for formulation, manufacturing, testing, and lifecycle decisions, compared to the Technical Data Sheet (TDS), which is concise and fact-based.

It serves as a link between regulatory requirements, quality assurance, and formulation science. For regulatory organizations, the PSF works as an evidence-based justification of the product's safety, efficacy and reliability. It also serves as a knowledge base for companies, helping audits, troubleshooting, and lifecycle management. [9]

3.2 Definition of PSF

A well-organized scientific report that explains the purpose of each product decision. The compilation of risk management results, validation, development data, and formulation studies. A supplemental file for internal audits, inspections, and regulatory submissions.

3.3 Purpose of PSF

- To provide scientific explanations for formulation and process decisions.
- To combine quality, clinical, and preclinical data into a logical argument.
- To serve as an evolving document that supports updates, modifications in regulations, and the product's lifecycle.
- To prove conformity to pharmacopoeial standards and ICH guidelines (Q8, Q9, Q10).

3.4 Scope of PSF

Table no 1: Areas with Detail Covering and their Purposes.

S.no	Area	Details Covered	Purpose
1	Formulation Development	Compatibility studies, dosage form justification,	Justifies product design.

		and excipient selection	
2	Manufacturing Process	Important process variables and control techniques	Ensures GMP compliance and reproducibility.
3	Analytical Studies	Impurity profiling and test method validation.	Indicates that the results are accurate.
4	Stability Testing	Real-time and accelerated studies.	Improves storage and shelf life.
5	Risk Management	ICH Q9 tools such as Ishikawa and FMEA.	Identifies and reduces risks.
6	Specifications	Limit justification, link to TDS and pharmacopoeias	Ensures adherence and consistency.
7	Lifecycle Management	Improvements once approval and technology transfer.	Maintains the product's conformity to rules.[10,11]

3.5 PSF Connection to Common Technical Document (CTD)

The PSF offers additional scientific justification that supports CTD Module 3 (Quality), but it will not submitted as a stand-alone regulatory file:

- M3.2.S: Drug Substance: provides analytical data, characterization, and specifications.
- M3.2.P: Drug Product: includes information on stability, manufacturing process, formulation development, and specifications.
- Appendices containing equipment, excipients, and raw material details (M3.2.A).

3.6 Relation with Regulatory Framework

The PSF approves the Common Technical Document (CTD), especially Module 3 (Quality), but it is not a formal regulatory submission. It ensures internal consistency, ensuring that data is both scientifically sound and ready for approval when it is transfer into CTD.

3.7 Role of QA in PSF

- The presented scientific data is all verifiable, accurate, and traceable.
- The documentation complies to the ALCOA+ data integrity principles.
- (ICH Q9) Risk assessments are carefully covered.
- By cross-referencing with TDS, inconsistencies can be prevent. [12]

3.8 Benefits of PSF

- All decisions are justified by scientific proof.
- Eliminates the risk of regulatory rejected applications.
- It is use as reference and training material.
- Promotes post-approval updates and continuous improvement. [13]

3.9 Challenges in Preparing PSF

- Gathering data from multiple teams (R&D, QA, Clinical, and Regulatory).
- Ensuring consistency with constantly evolving rules and regulations.
- Maintain it up to date while post-approval changes carried out. [14,15]

3.10 Module 3 (Checklist)

- ✓ Objectives and scope are clearly defined.
- ✓ A detailed account of formulation development.
- ✓ Based on (ICH Q9) risk assessments are included.
- ✓ Comparison of specifications with pharmacopoeias and TDS.
- ✓ Includes the stability summary.
- ✓ Provide sources (reports, scientific papers, guidelines).

➢ GUIDELINES

- ICH Q8 (R2): Pharmaceutical Development.
- ICH Q9: Quality Risk Management.
- ICH Q10: Pharmaceutical Quality System.
- FDA. (2020). Chemistry, Manufacturing, and Controls (CMC) Information.

MODULE 4: TDS & PSF REGULATORY FRAMEWORK

4.1 Why Regulatory Framework Matters

The technical evidence used by regulators, auditors, and internal stakeholders to determine whether a

product is safe, accurate, and suitable for the market is found in TDS and PSF, which aren't just internal documents. The correct regulatory framework defines what should be included, how to structure it, and the standard of proof for every claim. Plenty of last-minute requests and delays can be avoid if your TDS/PSF follows to the proper guidelines and reasoning up front. [16, 17]

4.2 Understanding of Global Foundations

4.2.1 ICH Family (Development & Quality Core)

- ICH Q8 (Pharmaceutical Development):
  It explains what information about pharmaceutical development and formulation explanation should be included in regulatory submissions. It provides guidance on how much growth detail should be provide in Module 3 and therefore, what should provide in the PSF. To explain the choice of excipient or process parameter, use Q8. [18]
- ICH Q9 (Quality Risk Management):
  It provides expectations and tools (risk matrices, FMEA) for maintaining how you have identified and handled risks, which affect product quality. PSF supposed to present risk assessments that support specifications and control procedures. [19]
- ICH Q10 (Pharmaceutical Quality System):
  It explains how to incorporate documentation into a quality system. Improvement management, CAPA, and continuous improvement are all pertinent while the PSF is a living document that is use throughout its lifecycle. [20]
- ICH M4 / M4Q (CTD):
  It determines the format and location of high-quality data in regulatory dossiers. Short, ready-reference criteria that match CTD Module 3 entries are frequently discovered in the TDS; the internal narrative supporting those Module 3 items is called the PSF. When mapping the TDS or PSF information to the submission, follow to M4Q. [21, 22]

  Note: Always remember the CTD mapping: claims in the PSF should include exact cross-references for batch records, stability reports, Module 3 documents, and validated methods.

4.3 What is the same and what is different with (Regional Regulators)?

4.3.1 FDA (United States)

Modern quality systems, validated methods, and CMC completeness are all highly valued for the FDA. They publish multiple sets of CMC guidelines and ask for scientific support for shelf life and specifications. It is recommended to have an early conversation with the FDA regarding novel methods (QbD, continuous manufacturing). [23, 24]

4.3.2 EMA (European Union)

For Module 3, EMA implements its M4Q guidelines and ICH standards. EMA documents frequently include complete specifications justification, stability, and impurity expectations. Make a note regarding any regional differences (labelling, excipient rules) in the regional information section of your PSF (3.2.R). [25, 26]

4.3.3 CDSCO/Schedule M (India)

Although India is moving closer to ICH principles, local laws (including Schedule M for GMP and CDSCO guidelines) are still important for site approval and specific dossier requirements. Make sure the TDS/PSF specifically lists meeting the Schedule M and CDSCO requirements intend to launch in India. [27, 28]

4.3.4 World Health Organization (WHO)

When looking for WHO prequalification or in middle and low income markets, WHO TRS (Technical Report Series) and its annexes offer advice on accuracy of data and documentation practices. Regulators now usually accept the WHO's data integrity standards (ALCOA+). For maximal cross-market consistency, obey WHO guidelines. [29]

Note: Regional variations primarily affect format specifics, naming, and certain local administrative requirements, while the scientific core (ICH) is standardized. These should always be mentioned in PSF under the specific "regional considerations" subsection.

4.4 Linking Guidelines to TDS and PSF Content

- TDS (short for operational):
  Product identity, composition, finished product specifications, packaging, storage, and method

references. Compendial monographs and ICH Q6A as a guide.

- PSF (detailed scientific support): stability program (Q1A), process controls (Q10, Q11), analytical method validation (Q2, Q14), formulation justification (Q8), and risk assessments (Q9).

For Example: if the TDS indicates that "Assay (HPLC): 98.0–102.0%," the PSF should present the following research documentation: method validation report (ICH Q2), batch testing outcomes, system suitability, justification for limits (such as the API decomposition profile), and risk assessment if close impurity thresholds (ICH Q9). [30]

4.5 Electronic records, Data Integrity, and Inspections

Regulators regularly inspect data systems and documentation. Expectations in modern times include:

1. All records must adhere to the ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available). FDA and WHO guidelines insist on this.
2. Access control, e-signatures, and audit trails for LIMS and electronic lab notebooks. Make use of verified systems, maintain vendor, and SOP documentation available for review. [31]

Useful Steps: Maintain an evidence matrix with report IDs and page references that links each TDS or PSF assurance to a supporting file (COA, stability report, validation report, and batch record). Ensure that both the TDS and PSF have a revision record page and version control.

4.6 Challenges of Harmonization and Effective Solutions

Challenge: Pharmacopoeial differences (USP vs. IP), regional administrative variations, and changing expectations (updated ICH/eCTD) are among the difficulties.

Solution: Include involving regulators early on, adding a "regional notes" appendix to PSF, and using ICH as a baseline. [32]

4.7 A Helpful Checklist for getting TDS and PSF Ready for Regulatory Requirements

1. Before the draft is finished

- ✓ Identify the target markets and the relevant regulatory requirements (FDA, EMA, CDSCO, and WHO).
- ✓ Design a template for an evidence matrix (the statement → Original document ID → Page).
- ✓ Make sure that appropriate ICH guidelines and pharmacopeial monographs are available.

2. Draft Stage

- ✓ Attach the method validation report (ICH Q2), the justification (ICH Q6A), and the batch data for every TDS specification.
- ✓ Provide the risk assessment (Q9), control strategy (Q10), and formulation justification (ICH Q8) in PSF. [33,34]

3. Completion

- ✓ QA review and approval using version history and controlled signatures.
- ✓ Verify the consistency of the TDS and CTD Module 3 entries.
- ✓ Assemble the inspection package, including the stability summary, data system SOPs, evidence matrix, and verified analytical techniques. [35]

➢ GUIDELINES

- ICH Q8 (R2) — Pharmaceutical Development.
- ICH Q9 — Quality Risk Management.
- ICH Q10 — Pharmaceutical Quality System.
- ICH M4 / M4Q — Organization of the Common Technical Document (CTD), Module 3 (Quality).
- FDA: Chemistry, Manufacturing and Controls (CMC) guidance and CMC overview.
- WHO TRS 1033 — Annex 4: Guidance on data integrity (ALCOA+).
- Schedule M — Good Manufacturing Practices (India).
- CDSCO Guidance Document.

MODULE 5: TECHNICAL DATA SHEET (TDS) PHARMACOPOEIAL STANDARDS

5.1 Introduction

Legally recognized books of standards known as pharmacopoeias (BP, USP, IP, Ph. Eur.) define the standards for medicine quality.

These pharmacopoeial monographs must be complying with the Technical Data Sheet (TDS) in order to ensure:

i. Conformity to legal standards.
ii. Global uniformity in product specifications.
iii. Accessibility in the criteria for testing and release.

Product recalls, regulatory queries, and approval delays tend to be the result of an error between TDS guidelines and pharmacopoeial standards. [36]

5.2 Pharmacopoeia's function in TDS

Pharmacopoeias provide baseline standards. These are improve further by the TDS to include:

i. Requirements specific to a product (e.g., proprietary excipients).
ii. Validated techniques specific to the company, if pharmacopoeial methods are not employ.
iii. Tightened specifications when required in order to comply with regulations or manage risks.

Table No 1: Includes Section on Pharmacopoeia and What TDS Needs to Record

S.no	Section on Pharmacopoeia	What TDS Needs to Record
1	General Notices	Monographs' legal applicability and general techniques.
2	General Chapters	Methods to determine microbial limits, sterility, and dissolution testing.
3	Monographs	API and dosage form specifications unique for every product.
4	Standards of Reference	Use of reference materials from pharmacopoeia for validation. [37]

5.3 Standards of Pharmacopoeia Regarding TDS

5.3.1 Tests of Identification

i. The identity and chemical structure of the API must tested.
ii. TDS should indicate whether other techniques are validated or pharmacopoeial tests (UV spectroscopy, HPLC retention time, and IR) are used.

5.3.2 Assay (Active Ingredient Content)

i. In pharmacopoeias, assay methods are accept as the gold standard.
ii. Validated assay methods with acceptance limits (such as 98.0–102.0% of label claim) must specified in TDS.

5.3.3 Impurities

i. It is necessary to control heavy metals, organic contaminants, and residual solvents.
ii. TDS needs to coincide with pharmacopoeial impurity profiles and ICH Q3A/B.

5.4.4 Testing for Dissolution

i. Pharmacopoeias specify the dissolution test equipment, medium, and Q-values for consumption solid dosage forms.
ii. TDS must specify dissolution standards clearly and provide justification for any deviation.

5.4.5 Testing for microbes

i. Microbial limitations or sterility tests are required for both sterile and non-sterile products.
ii. TDS should show conformity to IP/Ph. Eur. chapters <71>, <61>, <62>, or equivalent versions. [38]

5.4 Challenges of Harmonization

Pursuing their goal of harmonization, pharmacopoeias differ as follows:

Table No 2: Includes the Tests and Impact on the TDS with different Pharmacopoeias

S.no	Tests	IP	USP	Ph.Eur.
1	Dissolution	Q = 80% in 30 min.	Q = 80% in 30 min.	Q = 75% in 45 min.

2	Impurities	Q = 80% in 30 min.	Aligned with ICH Q3.	Some APIs are a little stronger.
3	Microbial Limits	IP 2.2.9 Microbial Contamination in Nonsterile Products.	<61>/<62>	Ph.Eur.2.6.12 Microbial Enumeration Test.

5.5 Practical Checklist for TDS Compliance

When preparing a TDS according to pharmacopoeial standards, make sure:

- ✓ Both API and ingredient monographs were correctly referenced.
- ✓ Test procedures that follow pharmacopoeial guidelines (or accepted alternatives).
- ✓ Pharmacopoeial ranges are used to support the acceptance criteria.
- ✓ Assay validation is perform using reference standards (USP/EP/WHO).
- ✓ For global launches, a harmonization strategy is in place.
- ✓ If pharmacopoeial guidelines are update, change control should documented.

MODULE 6: PRACTICES FOR DATA INTEGRITY AND DOCUMENTATION

6.1 Introduction

The accepted standards (ALCOA+), common causes of failures, the importance of data integrity, and practical, audit-ready techniques for laboratory, QC, manufacturing, and regulatory documentation are all covered in this module. It contains recommended readings, an evidence-matrix template, sample SOP headings, and preparation steps for evaluations.

6.2 Importance of data integrity

All quality decisions, particularly those regarding specifications, releases, stability, reviews, and regulatory submissions, can based on data integrity. Regulators will reject the conclusions if the data is inaccurate, which might compromise site licenses, product releases, and batch dispositions. Data integrity failures result in notification emails, import alerts, and product recalls, according to recent regulatory enforcement actions. Thus, maintaining data integrity protects both patient safety and business reputation.

6.3 Fundamentals of ALCOA+

The ALCOA+ mnemonic will accepted by the industry as the useful benchmark for data integrity: ALCOA+ stands for [39,40]

A= Attributable
L= Legible
C= Contemporaneous
O= Original
A= Accurate
+ = Complete, Consistent, Durable, and Available

- Attributable: when and by whom it was recorded (name, signature, or e-signature).
- Legible: readable either during or after inspection.
- Contemporaneous: recorded now the action took place.
- Original: a true copy that have been verify or the original record.
- Accurate: right, with proof of approval or review.
- +: Complete, Consistent, Durable, and Available (complete dataset, consistent entries, long-term retention, and on-demand retrievability). [41,42]

Note: Make ALCOA+ a standard checklist for all kinds of records, for example equipment logs, batch records, LIMS entries, chromatograms, and bench notebooks.

6.4 Systems and technology

❖ What should be verified and how?

Whether the process is paper-based, hybrid, or entirely electronic will determine your approach.

- For Paper systems:
  i. Apply serial numbering, controlled forms, defined retention, and clarified sign/initial requirements.

ii. Be sure to strike through a single line with the date, your initials, and the reason for any corrections. Avoid using correction fluid.

- For Hybrid systems (Electronic + Paper):
  i. Printouts need to be marked as "authenticated copies" and compare to the original electronic documents; the original needs to be maintained
  ii. Make sure SOPs describe the creation, review, and filing of paper copies.
- For Electronic systems (ELN, CDS, LIMS, MES):
  i. Validate computer systems using a CSV (Computer System Validation) phase: URS → functional specifications → IQ/OQ/PQ → SOPs → backup/restore → retirement.
  ii. Assure features such as unique user IDs, secure backup, role-specific entry, enforced session timeouts, thorough auditing, timestamping, and strong passwords.
  iii. Use electronic signatures whenever possible when combined with written policies that follow to 21 CFR Part 11(Electronic signature) or its regional equivalents. [41,43]

6.5 Modes of Failure

❖ What inspectors look for?

Case studies and regulatory reviews bring attention to these enduring issues.

i. "Soft" deletes and manual overwrites without a reason.
ii. Missing raw data (instrument logs, chromatograms).
iii. Audit trails that are either disabled or incomplete.
iv. Post-dating or backdating entries.
v. The same employee entering and approving important results is an example of poor job segregation.
vi. Spreadsheets that are uncontrolled and contain external links or hidden formulas. [44,45]

Note: Most inspections findings can be avoid by taking care of these.

6.6 Evidence Mapping and Flow of Data

Make an Evidence Matrix that connects each TDS/PSF claim you have to make both raw and derived data, such as the dissolution Q value or assay limits:

- Evidence Matrix with Sample Headings
  i. Claim or Statement (e.g., Assay specifications).
  ii. ID of the source document (e.g., the validation method reports).
  iii. Location of raw data (e.g., Chromatography file / Instrument ID / Application ID).
  iv. Report summary (e.g., Stability report).
  v. Agreement (name, position, date).
  vi. Location of the archive (file server path or LIMS ID). [46,47]

Note: The quickest way to satisfy auditors and gather TDS/PSF documentation for CTD Module 3 is to keep this matrix updated.

6.7 SOPs and Documentation Procedures

Make detailed SOPs that address the following subjects (each SOP should include definitions, responsibilities, scope, a systematic process, forms, and records):

i. SOP: Data Integrity Standards: describes ALCOA+, roles, and penalties.
ii. SOP: Laboratory Documents & Records: handwriting guidelines, corrections, and template attached.
iii. SOP: Computer System Validation (CSV): ELN/LIMS/ERP validation lifecycle.
iv. SOP: Electronic Signatures & Authentication: guidelines for passwords, account lifecycles, and e-signatures.
v. SOP: Audit Trails & Review: The frequency and procedure for conducting periodic audit trail reviews (who, how, and retention).
vi. SOP: Data Backup, Maintenance, & Retrieval: disaster recovery, encryption, backup schedule, and retention period.
vii. SOP: Spreadsheet Control: use of templates, locked rows, change log, and steps for review and approval.
viii. SOP: Change Control for Analytical Methods: Link to versioning and method validation record.
ix. SOP: Raw Data Archiving: chromatogram, spectrum, and image layout, indexing, and retrieval procedures.

x. SOP: Training & Competency: induction and recurring data integrity evaluation. [48,49]

Note: Every SOP ought to be included in the organization's quality management system (QMS) and make reference to regulatory guidelines.

6.8 Instructions and Customs

Without people, documentation policies are ineffective. Develop expertise and an honest culture by:

i. Normal instruction in SOPs and ALCOA+.
ii. Workshops that are hands-on (actual instances of inadequate documentation and proper corrections).
iii. Line management accountability requires supervisors to sign and review documents on a regular basis.
iv. Methods for anonymous reporting of suspected data problems. [50]

6.9 Management of Investigations, CAPA, and Deviations

When irregularities in the data show up:

i. Contains: safeguard the information and stop additional alterations.
ii. Examines: Take a look back to the source: environment, method, instrument, and analyst.
iii. Document: complete investigation report with supporting documentation, timeline, impact analysis, and approvals.
iv. CAPA: stands for corrective and preventive actions; staff retraining and SOP updates.
v. Regulatory reporting: alert QA and regulatory as needed if the anomaly impacts submitted data or released products. [51]

6.10 Checklist for report headers (for every analytical run)

- ✓ ID of the instrument and its status (date of calibration).
- ✓ Name and signature of the analyst (e-signature).
- ✓ Version and method ID.
- ✓ Batch numbers and sample IDs.
- ✓ Results of system suitability (pass/fail).
- ✓ Attach printouts and raw chromatograms.
- ✓ Block of review and approval signatures.

MODULE 7: TECHNICAL DATA SHEET (TDS) PREPARATION WORKFLOW

7.1 Introduction / Purpose

Creating a concise, ready for regulators Technical Data Sheet (TDS) for a pharmaceutical product and managing the workflow to ensure that the TDS content is precise, justified, and identifiable into the Product Science File (PSF) and CTD Module 3 are the topics covered in this module. Data collection, technique connection, QA review, version control, and final sign-off all covered in the workflow.

7.2 What a TDS Needs to Accomplish?

To provide manufacturing, quality control, and regulatory teams with a single point of reference, a TDS is a succinct technical declaration of product characteristic and quality controls. It needs to offer following:

i. Identification of the product (INN, brand name, strength, and dosage form) Medical Safety.
ii. Composition (amounts of excipients and API(s)).
iii. Specifications for release and shelf life along with test methods (microbial, dissolution, impurities, and assay).
iv. Conditions of storage and packaging.
v. Listing of stability summary and approved analytical techniques.
vi. PSF cross-references and supporting documentation (batch data, stability reports, and method validation). [52]

7.4 The Workflow of TDS (An Overview)

i. Define the Kick-off & Scope: Including the target markets and legal requirements.
ii. Collection of Data: Collect formulation records, analytical techniques, Reports of validation, data of stability, batch release data, and packaging specifications.
iii. Drafting of TDS: The first version is created by the draft TDS (technical writer/RA) using the approved template.
iv. Cross-functional Audit: R&D, QC, QA, Manufacturing, and Regulatory Affairs examine technical accuracy and verified links.
v. Evidence Mapping: Connect each TDS claim to PSF/CTD evidence (stability, batch data,

and method validation) through evidence mapping.

vi. Quality Assurance Verification & Sign-off: Final checks for integrity of data, version control, and regulatory compliance carried out by QA during verification and sign-off.

vii. Release and Version Management: distribute to stakeholders, archive previous versions, and publish controlled TDS. [53]

7.5 Detailing and Systematic Workflow

- Step 1: Kick-off & Project Brief
  i. Appointment of TDS owner (typically Regulatory Affairs or QA) and a technical lead from R&D/QC.
  ii. Determine pharmacopeial guidelines and specific regulatory requirements by designating a technical lead from R&D/QC and the TDS owner, usually Regulatory Affairs or QA. Document scope includes dosage form, strength, target nations, intended marketing claims, and primary packaging.
- Step 2: Collection of Data & Gap Analysis
  i. Retrieve the following important documents compendial monographs (USP/IP/EP), accelerated and long-term stability reports (ICH Q1A), batch release certificates, composition master records, method validation reports (ICH Q2), and packaging compatibility studies.
  ii. Conduct a gap analysis by contrasting the evidence that is currently available with what the TDS requires. Mark incomplete stability points, missing validations, or unreliable packaging claims.
- Step 3: Drafting of TDS

Make use of a standard format (title section, product identity, composition, specifications table, methods introduction, storage/packaging, remarks). A normal TDS specification table must display, For Example

Table No 1: TDS Draft

S. No	Test	Method Reference	Acceptance Criteria (shelf/release)	Document Source ID
1	Identification (API)	USP <197> IR spectroscopy	Spectrum complies with the API reference standard.	ID-REPORT-01
2	Appearance	In-house method QC-DESC-01	Tablet, white to off-white, without cracks or discoloration.	Batch COA-001, STAB-01

Note: Include not only the method name but also the test method ID and version for every specification. Cite the edition if a pharmacopoeial method is employ.

- Step 4: Cross-functional Audit
  i. Distribute TDS among Regulatory Affairs, Manufacturing, QA, QC, and R&D. Make use of an inspection checklist that guarantee: PSF/CTD alignment, unit consistency, accurate method forms, and packaging details.
  ii. Keep track of reviewer remarks in a controlled evaluation log. Update the TDS and respond to comments with supporting documentation.
- Step 5: Evidence Mapping
  i. Provide a stability overview in the PSF/appendix that includes the following important findings: photo stability, forced degradation data when necessary, and actual and accelerated study outcomes (ICH Q1A). Define TDS shelf limits and storage conditions using these data.
  ii. Document the rationale and any planned post-approval commitments (such as continuous stability batches) if the suggested shelf life exceeds the data that is currently available. Any extrapolation must be justified in the eyes of regulators.
- Step 6: Quality Assurance Verification & Sign-off
  i. Evidence mapping: Each specification entry needs to include a link to a minimum of one supporting document.
  ii. Data integrity: checks include audit trails, verified systems for electronic records, and the availability of raw data.
  iii. Version control: designate a distribution list, revision history, effective date, and controlled document number.
  iv. Regulatory check: confirm that a regional notes appendix addresses regional differences (such as pharmacopoeial method differences).
- Step 7: Release and Version Management

i. With read/write permissions specified in the QMS, release the controlled TDS in the Document Management System (DMS). As necessary, communicate with external partners (such as contract manufacturers), QC, QA, and manufacturing.
ii. For any upcoming updates, keep a change control log and archived previous versions. [54]

7.6 Tools and Templates

i. Cover page, structure, specification table, processes references, packaging & storage, notes, and version control are all included in the TDS template. View examples of required fields and style in the public domain.
ii. Statement → Source ID → raw data path → Approver is the evidence matrix. Connecting TDS to PSF/CTD requires this.
iii. Lacking stability or validation items with owner and deadline in the gap log template.
iv. Examine the following: lot traceability, pharmacopeia edition, units, and method IDs, and packaging codes. [55]

7.7 Schedules and Project Preparation

A typical timeline for a TDS that is ready for the market (for a simple generic oral solid dosage form with full data) is as follows:

i. Launch and data gathering: one week.
ii. Evidence collection and gap analysis: 1-3 weeks (depending on missing studies).
iii. TDS drafting: 2-3 days.
iv. Resolution and cross-functional review: 1-2 weeks.
v. Release and QA confirmation: 3–5 business days. [56]

7.8 Roles & Responsibilities (RACI clear)

RACI stands for Responsible, Accountable, Consulted, and Informed.

- Responsible: Technical Lead (R&D/QC), Regulatory Affairs (owner of TDS).
- Accountable: QA head for final approval.
- Consulted: Manufacturing (process), QC (methods), and Packaging (container closure).
- Informed: Manufacturing, Supply Chain, and Outside Partners. [57]

Note: Delays in handoff are avoid by having this RACI documented.

7.9 Checklist for Final Confirmation Prior to Release

✓ Every specification entry includes a validation reference and method ID.
✓ Storage conditions and shelf limits are support by stability data.
✓ The evidence matrix is finished and available.
✓ After a QA review, a signature is use (with verified signatory authority).
✓ Updates to the distribution list and document versioning.

MODULE 8: PRODUCT SCIENCE FILE (PSF) PREPARATION WORKFLOW

8.1 Introduction / Purpose

This module walks through the process of creating a Product Science File (PSF) that is ready for regulators. Roles and duties, the order of tasks, evidence and documentation connection, safety and regulatory controls, standard timelines, common pitfalls, and mitigations are all covered. A well-defined PSF workflow expedites CTD preparation, lowers regulatory inquiries, and makes launch readiness audit-ready and provable.

The company's internal, scientific justification for product design, manufacturing, and control strategy is known as the PSF. The PSF offers traceable proof for the claims made in the Technical Data Sheet (TDS) and endorses the CTD Module 3 (Quality). Throughout the product lifecycle, the PSF needs to be organized, evidence-mapped, auditable, and kept up-to-date.

8.2 The Workflow of PSF (An Overview)

i. Launch of the project and definition of its scope.
ii. Data gathering and inventory of evidence.
iii. Drafting a scientific narrative (formulation, process, and analytics).
iv. Risk management and assessment plan (QRM).
v. Linking data analysis and stability evidence (validation & studies).
vi. Technical approval and cross-functional review.

vii. Release, version control, and QA verification.
viii. Archive, update, and maintain the lifecycle. [58,59]

8.3 Detailing & Systematic Workflow

- Step 1: Kick-off & Project Brief
  i. Assign an expert lead (R&D/formulation lead) and a PSF owner (usually Regulatory Affairs or QA). Product names, dosage forms, strengths, target markets, submission routes, and deadlines are all included in the document scope.
  ii. Choose a PSF template that corresponds with the CTD M3 headings. Determine the original version and document control number.
- Step 2: Collection of Data & Gap Analysis
  i. Gather the following sources: research reports, preparation documents, formulation research, process development documents, method development and validation documents, stability reports (both short-term and long-term), batch records, compatibility with packaging, supplier certifications, and excipient monographs.
  ii. Make an evidence list (spreadsheet) that includes each source document's unique ID, file location, owner, and brief description. The Evidence Matrix is built upon this.
- Step 3: Scientific Description of PSF
  i. Utilize the PSF template that has been mapped to the CTD M3 headings: development history, product description, detailed summaries of drug substances and products, manufacturing procedure and controls, strategy for control, analytical techniques and verification, Program for stability and rationale, packaging, Appendices and regional considerations.
  ii. Write a succinct, targeted narrative for each subsection is support by specific evidence citations (use Evidence IDs). Avoid superfluous repetition and use clear technical language.
- Step 4: Risk Assessments & Control Strategy

  Determine the impact and likelihood of failure modes on every identified CQA by performing QRM (risk matrix or FMEA). Record the suggested monitoring plan and controls (process, analytical, and in-process checks). The PSF's control strategy section should guide by the risk assessment, which should also support the specification limits.
- Step 5: Integrate Stability and Analytical Evidence

  Attach the batch assay data, stability summaries, and method validation for each PSF claim regarding the quality of the product (such as assay range, impurity limits, dissolution Q value, and shelf life). To display direct links, utilize the Evidence Matrix:

  PSF statement → Method ID → Validation report → Location of raw data → Approver.

- Step 6: Cross-functional Audit

Distribute the draft PSF to the following parties involved: R&D, QC, Manufacturing, QA, Regulatory Affairs, Supply Chain, Packaging, and Pharmacovigilance (if applicable). Keep a controlled audit log of your comments and make sure they are resolved with supporting documentation or a mutually acceptable explanation. Save the names, roles, dates, and sign-off status of the reviewers.

- Step 7: Quality Assurance Verification & Sign-off

QA verifies the completeness of the evidence, document numbering, version control, and data integrity. A final checklist should completed by QA, which includes evidence of all claims, signatures, SOP compliance, and CSV approval for electronic records. Following QA approval, archive earlier drafts and publish the PSF as a controlled document.

- Step 8: Regulatory Application and Lifecycle Maintenance

PSF is dynamic and have to update with new accuracy data, post-approval modifications, process enhancements, and method modifications. Use change control to keep track of updates; provide the Evidence Matrix and reflect modifications to the PSF revision history. During submissions, fill out CTD Module 3 with PSF content. [54, 60]

8.4 (Template) Recommended Table of Contents for PSF

S.no	Content
1	Product name, formulation, and controlled document information on the cover page.
2	History of revisions and approvals.
3	One-page executive summary.

4	Description of the product and its purpose.
5	Justification and history of development (link to studies).
6	Details about the drug substance (manufacturing, characterization)
7	Details of a drug product i. Composition of the formulation ii. Development of preformulation and formulation. iii. Controls and flow of the manufacturing process (process steps, CPPs) iv. System of packaging and closure.
8	Specifications and control strategy (referring to TDS).
9	Methods of analysis and validation summary.
10	Program for stability and justification for shelf life.
11	Risk management (summaries of QRM).
12	Regional factors (if any).
13	Appendices (method reports, supplier certificates, batch data references, and stability study reports).
14	Matrix of Evidence (or individual indexed file). [61]

8.5 PSF Preparation Workflow (Flowchart)

Start: Project Kick-off & Scope
↓
Collection of Data
↓
Gap Analysis ← If gaps, assign studies → Conduct Missing Studies
↓
Scientific Drafting of PSF
↓
Risk Assessment & Control Strategy (QRM)
↓
Integrate Stability & Analytical Evidence
↓
Cross-functional Audits (R&D/QC/Manufacture/RA/QA)]
↓
Resolve Comments / PSF Updating
↓
QA Verification & Final Approval Sign-off
↓
Publish Controlled PSF / Archive Previous Versions
↓
Use for CTD / Update during Lifecycle
↓
Finished

8.6 Schedules and Project Preparation

For a generic consumed solid dosage form that is well established and has the most data available:

i. Start and duration: one to two days.
ii. 1-2weeks for data collection and gap analysis.
iii. PSF (first complete draft) drafting: 1-2 weeks.
iv. Linkage between QRM and evidence: 3–7 days (concurrent).
v. Resolution and cross-functional review: 1-2 weeks.
vi. Release and QA sign-off 3-5 business days. [56,62]

8.7 Roles & Responsibilities (RACI clear)

RACI stands for Responsible, Accountable, Consulted, and Informed.

- Responsible: Technical Lead (R&D/QC), Regulatory Affairs (owner of PSF).
- Accountable: QA head for final approval.
- Consulted: Manufacturing (process), QC (methods), and Packaging (container closure).
- Informed: Production, the team responsible for regulatory submissions and outside CMOs or CROs as required. [57]

MODULE 9: QUALITY ASSURANCE IN TECHNICAL DATA SHEET (TDS) & PRODUCT SCIENCE FILE (PSF)

9.1 Introduction

The Technical Data Sheet (TDS) and Product Science File (PSF) are two essential documents that document and convey the quality and scientific basis of a new pharmaceutical product. Both having different functions, they are both in need of quality assurance (QA). These documents encounter the risk of becoming inconsistent, lacking, or not meeting regulatory requirements without quality assurance (QA), which could cause approvals to be delay or possibly rejected.

9.1.1 The Technical Data Sheet (TDS)

The TDS is mainly a factual document. It offers specific information about formulation composition, specifications, analytical test procedures, acceptance standards, necessary packing materials, and storage conditions. Because the TDS is reliable, mistakes or discrepancies could have major repercussions. Manufacturing and regulatory reviewers might doubt the accuracy of the product's quality profile, for instance, if test limits are inaccurate or impurity thresholds differ from validation reports. In order to ensure traceability, confirm accuracy, and preserve uniformity between the TDS along with supporting documentation such as pharmacopeial monographs and batch manufacturing records, quality assurance (QA) is essential.

9.1.2 The Product Science File (PSF)

In contrast, the PSF is a document that provides both scientific and narrative support. Along with gathering information from preclinical and clinical research, it also offers the justification for formulation decisions, production design space, control methods, and risk evaluations. The PSF describes how the product's quality, safety, and effectiveness were determined as well as the rationale behind the decisions made. In this case, QA oversight guarantees that all references are traceable, all claims supported by verified data, and the narrative aligns with the relevant regulatory submission modules, particularly CTD Modules 2 and 3. [63]

9.1.3 The Regulatory Agencies in TDS & PSF

Companies expected by regulatory bodies like the FDA, EMA, and CDSCO to prove not only the caliber of the product but also the accuracy and dependability of the data that used to support its approval. Because of this, TDS and PSF QA oversight is essential. Accurate and consistent documentation of specifications, development justification, and risk management techniques emphasized in the ICH guidelines (Q6A, Q8, and Q9). As a result, quality assurance is a continuous process that integrated into the drafting, review, and finalization of both TDS and PSF rather than existing as a distinct step at the end.

In practical terms, QA unites cross-functional teams from manufacturing, research and development, regulatory affairs, and quality control to guarantee that TDS and PSF are not only technically sound but also prepared for regulations. QA protects the dependability of these documents by implementing records management procedures, audit trails, review by peers, and risk-based verification. In the end, QA's role in TDS and PSF is about establishing trust, among regulators, healthcare providers, and especially among patients who depend on the product's efficacy and safety. [64]

9.2 Quality Assurance in Technical Data Sheet (TDS)

Important QA checkpoints for TDS preparation:

i. Specification Accuracy: Verify that analytical procedures, techniques, and acceptance criteria adhere to internal or validated pharmacopeial standards (ICH Q6A).
ii. Version Control: TDS documents need to adhere to stringent document management systems that include change histories and version numbers.
iii. Cross-Verification: Laboratory notes and batch manufacturing records (BMR) must use to confirm the results of analyses, manufacturing directions, and control strategies.
iv. Reliability: Every value (such as the impurity limit or assay range) needs to be connected to pharmacopeial references or source validation reports.
v. Uniformity Verification: Internal QA audits examine TDS in relation to related documents, such as stability reports, SOPs, and batch manufacturing records. [65,66]

9.3 Quality Assurance in Product Science File (PSF)

Since the PSF is more comprehensive and interpretive, it requires additional QA procedures:

i. Data Identification: Study IDs, research protocols, and statistical analysis reports should be use to cite all preliminary, clinical, and formulation data.
ii. Scientific Justification Review: QA makes sure that risk assessments (ICH Q8/Q9) back up explanations (such as excipient selection, design space, and control strategy).
iii. Regulatory Alignment: Verifies that ready for submission paperwork and PSF

narratives are consistent by cross-referencing with CTD modules, especially M2, M3, and M4.

iv. Accordance with TDS: PSF and CTD specifications must match those in TDS. Regulatory rejections could arise from discrepancies.

v. Controlled Improvements: Under change control, all scientific updates (such as new stability data) have to be examine, accepted, and added to the PSF. [67]

9.4 Tools and Procedures for QA

i. Document Control Systems (DMS): TDS/PSF versions are manage with the aid of software such as Veeva Vault (V Vault), Master Control, or Pharma Ready. [68]

ii. Audit Records: QA keeps track of TDS/PSF revisions, approvals, and archival audit trails.

iii. Internal QA Audits: Performed at pre-submission, review, and drafting milestones.

iv. QA (Risk based): Using ICH Q9 guidelines to pinpoint high-risk areas (such as impurity limits and bioequivalence data) known as risk-based quality assurance.

v. Multi-functional Review Committees: Including R&D, QA, QC, and regulatory ensures comprehensive quality assurance. [69,70]

9.5 QA Workflow for the TDS & PSF (Flowchart)

Start
↓
Drafting of Document (TDS/PSF by Authoring Team)
↓
Internal Audit (R&D, QC, Regulatory)
↓
QA Initial Review (accuracy check, data traceability check, regulatory references check)
↓
Corrections and Revisions
↓
Final QA Approval (sign-off, version control, archiving)
↓
Submission-Ready Document (aligned with CTD)
↓
Post-Approval Updates (Change control & revalidation if required)
↓
Finished

9.6 Overlap between TDS and PSF in Quality Assurance

This straightforward illustration demonstrates how QA makes sure that both documents independently uphold quality while also complying with regulations.

Diagram 1:



MODULE 10: COLLABORATION ACROSS FUNCTION

10.1 Introduction

A single department is not in charge of creating a Product Science File (PSF) or a Technical Data Sheet (TDS). The combined efforts of a pharmaceutical organization's technical, scientific, regulatory, and quality departments shown in these documents. Good cooperation between these departments guarantees that the PSF offers a thorough scientific narrative and the TDS stays a factual, unambiguous document, both of which are in line with industry norms and regulatory expectations. Without cooperation, discrepancies can arise: lab teams might produce data that is inconsistent with regulatory terminology, and regulatory affairs might find it difficult to support assertions if development scientists do not offer

adequate justifications. Therefore, creating trustworthy, consistent, and ready for submission TDS and PSF requires interdisciplinary teamwork.

10.2 Major Contributors to Function

i. Quality Assurance (QA)
   a) To assure data integrity, TDS and PSF drafts are review.
   b) Verifies traceability and adherence to IP, ICH, WHO, USP, and Ph. Eur. guidelines.
   c) Oversees version management and document control.

ii. Quality Control (QC)
   a) Creates and verifies the test procedures that are part of the TDS.
   b) Provides dissolution data, impurity profiling, stability study results, and certificates of analysis (CoA).
   c) Confirms the consistency and accuracy of the data.

iii. Research and Development (R&D)
   a) Gives formulation and design of methods a scientific justification.
   b) Provides development reports, formulation justifications, and experimental data.
   c) Connects innovative science with regulatory acceptability.

iv. Regulatory Affairs (RA)
   a) Converts technical information into language that complies with regulations.
   b) Verifies that TDS/PSF content corresponds with CTD modules, particularly 2.3, 3.2.S, and 3.2.P.
   c) Complies with international submission standards.

v. Preclinical and Clinical Teams
   a) Provide information on safety, efficacy, pharmacokinetics, and pharmacodynamics.
   b) Participate in the PSF's (benefit-risk evaluation) justification sections.

vi. Production and Manufacturing
   a) Provides information on process validation, equipment, batch records, and the viability of scaling up.
   b) Guarantees alignment with procedures for control and manufacturability. [71]

10.3 Challenges in Cross-Functional Collaboration

a) Data Storage: When teams operate independently, the result may be contradictory or fragmented data.
b) Collaboration Gaps: Scientific teams frequently use technical terms that regulatory writers do not understand.
c) Version Control Problems: Without centralized tracking, there may be several document versions.
d) Limited Time: Teams may rush due to regulatory deadlines, which raises the possibility of mistakes. [72]

10.4 Techniques for Successful Teamwork

a) For version control, set up an integrated document management system (DMS).
b) To ensure content alignment, hold frequent cross-functional review meetings.
c) To standardize contributions, use standardized templates for TDS and PSF.
d) To make roles more clear, use RACI (Responsible, Accountable, Consulted, and Informed) matrices.
e) Use quality-by-design (QbD) guidelines to make sure documentation incorporates scientific support. [73,74]

10.5 The Workflow Collaboration



MODULE 11: DOCUMENTATION RISK MANAGEMENT

11.1 Introduction

A structured, risk-based method called documentation risk management (DRM) makes sure that all documents—including the PSF, TDS, SOPs, batch records, study reports, and electronic records—are accurate, comprehensive, dependable, and accessible when needed. To ensure that resources are direct toward the records and controls that are most important for patient safety, product quality, and regulatory compliance, DRM brings quality risk management (QRM) principles to documentation.

The Project Management Institute, the largest professional association devoted to the field of project management, has identified risk management as one of the eight main components of the Project Management Body of Knowledge (PMBOK). [75]

11.2 Importance of Documentation Risk Management

i. Regulators demand that a TDS/PSF statement trace back to validated reports and raw data; incomplete or faulty documentation results in delays, warning letters, and inspection findings.
ii. By reducing the likelihood of critical record failures and making effective use of QA resources, DRM transforms documentation conformity from an automatic checklist into a proactive, focused program.

11.3 Foundation of Regulations and Guidelines

i. ICH Q9 (Quality Risk Management): Offers the guidelines and resources needed to evaluate and manage hazards (hazard classification, risk assessment, evaluation, control, review). Apply Q9 principles to documentation (e.g., which document errors could affect the quality of the product).
ii. FDA/EMA/WHO: Data integrity and QRM guidelines are link to audit trail, CSV, ALCOA+, and documentation lifecycle expectations.
iii. PIC/S Guidance (PI 041-1): Guidance on data integrity describes data governance and specifically suggests using QRM for records and record risks; this is helpful for DRM frameworks. [75,76]

11.4 Scope: which records and systems to incorporate

i. Master documents: Materials from TDS, PSF, and CTD Module 3.
ii. Control documents: SOPs, method validation protocols and reports, and stability protocols and reports.
iii. Transactional documents: include CoA, batch manufacturing records (BMR), and batch packaging records.
iv. Analytical raw data: Chromatograms, spectra, instrument logs, and LIMS records.
v. Electronic files and systems: ERP, MES, ELN, LIMS, shared drives, and archived PDF reports.
vi. Supplier/CMO documents: Supplier COAs, QC reports, and stability data from contract labs. [76]

11.5 Step-by-step practical DRM Process



11.6 Documentation Templets & Tools

A. Simple spreadsheet columns in the DRM Register
i. ID
ii. Description of the hazard
iii. Possible effects (severity)
iv. Probability (occurrence)
v. Current detection controls
vi. Risk category, or RPN (High/Med/Low)
vii. Technical and administrative controls to be put in place
viii. Owner and the desired date
ix. Acceptance of residual risk (name/date)
x. Examine the date and the notes.
B. FMEA (Failure Modes & Effect Analysis). [77]
C. Evidence Matrix which is link with DRM documents

Link high-risk documentation documents to their initial data sources and control condition (backup's OK, audit trails enabled, CSV status).

11.7 Roles & Responsibility

i. DRM Manager (QA/Data Governance): oversees reviews, keeps the DRM register up to date, and reports to the QA board.
ii. R&D, QC, and RA document owners should make sure that controls are in place and that their documents are inventor.
iii. Technical implementation (access control, backups, audit trails) by the IT/CSV team.
iv. Senior Management: guarantee resources and accept residual risk. [78,79,80]

Short Summary

Records and data systems are subject to ICH Q9 QRM techniques through Documentation Risk Management. DRM makes TDS and PSF tenable, auditable, and inspection-ready by identifying risks, measuring them, implementing appropriate controls, and recording acceptance. This is a crucial part of continuing product lifecycle management and launch readiness.

MODULE 12: BEST PRACTICES & TYPICAL ERRORS

12.1 Introduction

Success in pharmaceutical quality assurance is contingent upon the consistency with which systems such as TDS (Technical Data Sheet) and PSF (Product Science File) are implemented and documented. Regulatory reviews frequently reveal that failures are typically trigger by routine errors, such as inadequate cross-functional communication, poor change control, or incomplete records, than by missing systems. Based on research papers, case studies, and regulatory guidance, this section offers a consolidated set of typical errors (what frequently goes wrong and results in inspection findings) and best practices (what consistently works across industry). [81, 82]

12.2 Importance of Best Practices

i. Assure adherence to data integrity standards (ALCOA+) and ICH Q8/Q9/Q10 expectations.
ii. Cut down on regulatory observations (PIC/S findings, EMA warning letters, and FDA 483s).
iii. Boost productivity to prevent expensive product launch delays.
iv. Boost trust in TDS/PSF filings by making sure they are traceable and defendable. [83]

12.3 Best Practices

A. Documentation
   i. Always use ALCOA+ (Attributable, Legible, Current, Unique, Accurate + Complete, Consistent, Durable, Available).
   ii. No uncontrolled Word or PDF drafts in email messages or local drives thanks to version control via DMS (Document Management System).
   iii. SOPs for audit trail reviews require regular checks of computer systems (LIMS, ELN, and MES).
   iv. Management of metadata that make sure that keywords, indexing, and archiving can done correctly.
B. QRM (Quality Risk Management)
   i. Implement risk-based classification (per ICH Q9R1); concentrate on records that are release- or regulatory-critical; not all documents require the same level of rigor.
   ii. Keep a risk register for records.
C. Cross- departmental cooperation
   i. Accountability is ensure by the TDS/PSF RACI matrix.
   ii. Meetings for the regular review of documents (QA, RA, R&D, Production).
   iii. Every team uses the same authorize version, making it a single source of truth.
D. Learning and culture
   i. Employees should receive refresher training on integrity of data and documentation procedures every 12 to 24 months.
   ii. Encourage a "right first time" mentality and discourage unrecorded corrections or backdating.
   iii. Learn by using case studies of assessment failures.
E. Technology guides
   i. Replace paper-intensive procedures with validated computerized systems (LIMS, ELN, and DMS).
   ii. Automate access control and backups.
   iii. Use dashboard KPIs, such as audit trail checks, percentage of past-due reviews, and document retrieval time. [84]

12.4 Typical Errors and their Consequences

Table No1: Errors, description and Consequences are Present below.

S.no	Type of Error	Description	Consequences
1	Incomplete Records	Missing of signatures and unchecked data.	Compliance gap & FDA 483 observation.
2	Uncontrolled Version	With no centralized control, draft TDS/PSF is being circulate via email.	Inconsistent information, regulatory inquiries, and submission delays.
3	Poor Change Control	TDS was update without PSF alignment.	Delays in RA filing, Inconsistency.
4	Retrospective entries/ Backdating	Later data filling without annotation.	Breach of data integrity then potential warning letter.
5	Over Documentation	Duplicate or unnecessary SOPs.	Error risk, confusion, and resource waste.
6	Training Gaps	Unaware of documentation standards, staff.	CAPA and Recurrent Deviation.

12.5 Root Cause of Documentation Error

Here is the Fishbone (Ishikawa) Diagram 1, which shows the root cause of error in documentation. [85, 86]



MODULE 13: DOCUMENT MANAGEMENT AND DIGITAL TOOLS

13.1 Introduction

Documentation for pharmaceutical product launches must be precise, timely, and compliant. Product Science Files (PSF) and Technical Data Sheets (TDS) previously handled on paper or with simple word processing software. However, digital document management systems (DMS) and electronic devices have become indispensable due to the complexity of drug development, globalization of supply chains, and heightened regulatory scrutiny.

In addition to guaranteeing adherence to data integrity standards, a strong document management plan boosts productivity, lowers errors, and facilitates more seamless regulatory submissions. [87]

13.2 Document Management's Function in TDS and PSF

i. TDS/PSF drafts, early versions, and final approvals are all keep in one central location.
ii. Version control makes sure that everyone is working from the identical record and avoids duplication.
iii. To ensure accountability, audit trails are used to record who made changes and when.
iv. Access control to safeguard private product data.
v. Adherence to WHO data integrity guidelines, EMA Annex 11, and FDA 21 CFR Part 11 regulations. [87, 88]

13.3 Important Digital Sources for Pharmaceutical Documentation

i. Quality Management System (QMS).
ii. Document Management System (DMS). [89]
iii. Electronic Lab Notebooks (ELN).
iv. Laboratory Information Management System (LIMS).
v. AI/ML Supported QC Tools.
vi. eCTD Publishing Tools. [90]

13.4 Best Methods for Managing Digital Documents

i. Adopt electronic systems that have verified to comply with Part 11 and Annex 11.
ii. Link LIMS → DMS → eCTD tools, for example, to integrate systems.
iii. Employees should be train to refrain from abusing systems (uncontrolled drafts, unofficial spreadsheets).
iv. Create uniform TDS and PSF templates for the entire company. [91]

13.5 Typical Errors in Digital Documentation

i. Over-reliance on IT in the absence of explicit SOPs "People circumvent controls even though the system is validated." [92]
ii. Lack of integration results from disconnected systems (laboratory uses LIMS, QA uses QMS, and RA uses Excel).
iii. Inadequate metadata management results in documents that are difficult to locate. [92,93]

MODULE 14: LAUNCH READINESS CASE STUDIES

14.1 Introduction

In the pharmaceutical industry, accurate research evidence, legal cooperation, and operational readiness are the keys to every successful product launch. Technical Data Sheets (TDS) and Product Science Files (PSF) have a direct impact on approval timelines, market entry, and compliance outcomes, as demonstrated by the study of real launch cases. In order to identify what worked, what did not, and how those lessons can inform future launches; this module examines a variety of real and hypothetical case studies that taken from academic analyses, white papers, and regulatory publications.

Compared to ten years ago, the demands of the contemporary automotive market demand that products be prepared for production in nearly half the time. This is the cause of the automotive industry's current time constraints and increasing overlap between project phases. Additionally, the automotive industry is currently in a chaotic state due to an ongoing decrease in budget and resources.

Prior to creating this set of indicators, the company's current strategy for Production Launch management examine:

i. Be in line with business needs and complement the current strategy.
ii. Determine what the tool can offer and what is lacking from the current strategy. [93, 94]

14.2 Objectives

i. Recognize how launch readiness is impact by TDS and PSF preparation.
ii. Determine typical bottlenecks and ways to mitigate them.
iii. Gain knowledge from regulatory observations and examples from the global industry.
iv. Convert results into useful checklists for upcoming launches. [96]

14.3 Readiness Investigation Path (Flowchart)

Beginning

↓

Project Initial Phase → Formulation & Analytical Design (TDS Drafting)

↓

QA Review & Cross-Functional Validation

↓

PSF Compilation (Data + Justifications)

↓

Regulatory Mock Audit & Readiness Assessment

↓

Final Submission → Launch Decision → Post-Launch Review

↓

Continuous Improvement Phase

14.4 The Launch Successful (Vaccines Division, 2020) - CASE STUDY 1

The Background, Key steps and Outcomes.

- Background

A multinational vaccine manufacturer got ready to introduce an innovative product in Europe. Under the guidance of ICH Q8/Q9/Q10 principles, cross-functional teams concurrently developed the PSF and TDS.

- Key Steps
  i. Complete formulation development based on QbD.
  ii. Centralized DMS with version control emerged.
  iii. Carried out simulated regulatory audits of the records.
- Outcomes
  i. There were no significant findings from the EMA inspection.
  ii. Time from submission to approval decreased by 18%.
  iii. Global filings use the "one-source" PSF as a reference. [97]

14.5 The Delayed Launch (Generic Oral Tablets, India 2021)

The background, Root Causes, Corrective Actions and Outcomes.

- Background

Due to differences between TDS and batch manufacturing records, a midsize generic

manufacturer encountered a six-month post-submission delay.

- Root Causes
  i. After scale-up changes, the draft TDS is not updated.
  ii. Excipient changes in PSF sections were not justified.
  iii. QA review only took place at the final moment.
- Corrective Actions
  i. Developed a SOP for version tracking.
  ii. Constituted a multidisciplinary document review group.
  iii. Role-based access control was implement in the DMS.
- Outcomes

The next submission has acceptable without any issues.

Showed the importance of ongoing TDS, PSF, and manufacturing record alignment. [98]

14.6 Regulatory Refusal (Biologic Injectable, FDA 2019)

The background, Identified issues, Preventive Actions and Key Takeaway.

- Background

Data integrity issues and missing analytical validation sections led to the rejection of a BLA from an early-stage biotech company.

- Identified Issues
  i. PSF's raw data links are missing.
  ii. Inadequate documentation of the analytical method.
  iii. No official change-control documentation.
- Preventive Actions
  i. Adopted documentation training based on ALCOA+.
  ii. e-LIMS is introduced to connect PSF sections to raw data.
  iii. QA participation is required starting in Phase II.
- Key Takeaway

Early development of a compliance culture is necessary; "retrofitting" documentation prior to filing is rarely successful. [99, 100]

14.7 Maturity Curve for Launch Readiness

Readiness from Low to High

Low Readiness ⟶ High Readiness

14.8 Similar Findings in Different Case Studies

i. The most common differentiator is documentation synchronization (TDS ↔ PSF).
ii. First-cycle approval rates are increase by cross-functional participation.
iii. Reduced data-integrity deviations are correlate with digital readiness.
iv. Consistency throughout the lifecycle is ensure by QA responsibility early in development.
v. Feedback loops after launch stop pre-launch problems from happening again. [100]

MODULE 15: FUTURE TRENDS

Complete digital transformation of TDS and PSF documentation is the direction of the future. To accelerate the preparation of documents, review, and submission, pharmaceutical companies increasingly use systems based on the cloud, artificial intelligence analytics, and automation tools. These technologies speed up and improve compliance in international markets while lowering manual labor and error rates. The use of block chain technology to preserve document validity and version control is another popular trend. It offers a transparent and impenetrable audit trail, which is in complete accordance with WHO GMP and ICH Q10 requirements for data integrity. Technical document structure also affected by the increasing significance of continuous manufacturing and Quality by Design (QbD). As documentation, moves from static to dynamic, future TDS and PSF formats may include real-time data collection, process control techniques, and lifecycle monitoring components.

Harmonization of regulations is another important area. Initiatives like Q12 (Lifecycle Management) and ICH M4 (CTD structure) are helping to standardize

documentation requirements worldwide. This streamlines the approval process for international product launches and lessens duplication.

Lastly, emphasis is currently set on sustainability and paperless operations. In addition to supporting environmental goals, the move to electronic documents, e-signatures, and electronic batch records guarantees quicker access as well as verification during inspections and audits.

CONCLUSION

The pharmaceutical industry's larger shift toward smarter, more integrated, and data-driven systems appeared in the development of TDS and PSF documentation.

These records will become dynamic knowledge resources that support the quality of products, safety, and lifecycle management in the upcoming years rather than static regulatory files.

Companies can increase their launch readiness and regulatory confidence by adopting digital innovations, predictive analytics, and standardized standards.

Instead of just finishing documentation, the emphasis will be on creating an ongoing scientific record that enhances product comprehension and decision-making throughout the entire process.

In summary, coordination, innovation, and intelligence are key to the future of TDS and PSF and will revolutionize the way pharmaceutical products are reviewed, documented, and introduced around the world.

REFERENCE

[1] https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/medical-launch-readiness.pdf
[2] https://www.deallus.com/wp-content/uploads/2019/01/Deallus-The-Three-As-of-Launch-Readiness.pdf
[3] https://www.mckinsey.com/capabilities/operations/our-insights/launch-excellence-everything-depends-on-flawless-operations
[4] https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf
[5] https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
[6] https://www.fda.gov/files/drugs/published/M4-Organization-of-the-Common-Technical-Document-for-the-Registration-of-Pharmaceuticals-for-Human-Use-Guidance-for-Industry.pdf
[7] https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m4q-common-technical-document-registration-pharmaceuticals-human-use-quality-step-5_en.pdf
[8] https://www.sciencedirect.com/science/article/pii/S1319016413001114.
[9] Patel H, Patel A, Prajapati V, Gajjar A. Preparation and review of chemistry, manufacturing and control (CMC) sections of CTD dossier for marketing authorization. Int J Drug Regul Aff. 2017;5(2):1-12.
[10] The future of regulatory filings: digitalization. AAPS Open. 2025;11(1):13.
[11] Palem C, Bandyopadhyay AK, Palem CR. Scale-up factors in the development and commercial execution of oral solid dosage forms: A current industry perspective. J Pharm Pharm Res. 2024;6(4):329–43.
[12] Khoja SS, Khoja S, Chauhan PH, Khoja FS, Khoja S. A Review on Creation and Handling of Data in Accordance with cGMP Requirements in Pharmaceuticals. PharmaTutor. 2017;5(5):64-69.
[13] Review Article On The Pharmaceutical Preformulation. IOSR J Pharm Biol Sci. 2024;19(1):1-12.
[14] Verma G, Mishra MK. Pharmaceutical preformulation studies in formulation and development of new dosage form: A review. Int. J. Pharma Res. Rev. 2016;5(10).
[15] Yadav P, Bahmani K, Pawar N, Sharma AA. Review on: Indian Pharma Regulatory System and List of New Drugs Approved by Central Drugs Standard Control Organization in the Year 2021 Till Date. Int. J. Pharm. Sci. Res. 2021;12:5642-51.
[16] EMA C. Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials. London, UK. 2006.

[17] Jordan D. An overview of the Common Technical Document (CTD) regulatory dossier. Medical Writing. 2014 Jun 1;23(2):101-5.
[18] Ermer J. ICH Q2 (R2): validation of analytical procedures. Method validation in pharmaceutical analysis: a guide to best practice. 2025 Apr 7:351-72.
[19] Lotllikar M. Quality risk management (QRM): A review. Journal of Drug Delivery and Therapeutics. 2013;3(2):149-54.
[20] Lipa M, O'Donnell K, Greene A. Managing Knowledge and Risk: a Literature Review on the Interdependency of QRM and KM as ICH Q10 Enablers. Level 3. 2020;15(2):3.
[21] Guideline IH. Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use M4. Geneva: ICH. 2004.
[22] Teasdale A, Borman PJ, Mullen AK. Regulatory highlights.
[23] Colgan ST, Watson TJ, Whipple RD, Nosal R, Beaman JV, De Antonis DM. The application of science-and risk-based concepts to drug substance stability strategies. Journal of Pharmaceutical Innovation. 2012 Dec;7(3):205-13.
[24] Wu C, Lee SL, Taylor C, Li J, Chan YM, Agarwal R, Temple R, Throckmorton D, Tyner K. Scientific and regulatory approach to botanical drug development: a US FDA perspective. Journal of Natural Products. 2020 Jan 24;83(2):552-62.
[25] Ramamoorthy A, Araojo R, Vasisht KP, Fienkeng M, Green DJ, Madabushi R. Promoting clinical trial diversity: a highlight of select US FDA initiatives. Clinical Pharmacology & Therapeutics. 2023 Mar;113(3):528-35.
[26] Li M, Sander S, Duan J, Rosencrance S, Miksinski SP, Yu L, Seo P, Rege B. Scientific and regulatory considerations in solid oral modified release drug product development. The AAPS journal. 2016 Nov;18(6):1406-17.
[27] Yu LX, Akseli I, Allen B, Amidon G, Bizjak TG, Boam A, Caulk M, Doleski D, Famulare J, Fisher AC, Furness S. Advancing product quality: a summary of the second FDA/PQRI conference. The AAPS journal. 2016 Mar;18(2):528-43.
[28] Guideline EM. Guideline on stability testing: stability testing of existing active substances and related finished products. CPMP/QWP/122/02, Rev. 1, 2003, 1/18; 2003 Jan.
[29] Sushma R, Ramakrishna G, Nagabhushanam MV, Pavani TS, Gowthami M, Challa A, Sanjuda SK, Devi MB. REGULATORY REQURIMENTS FOR THE REGISTRATION OF GENERIC DRUGS IN INDIA.
[30] Gordon J, Potthast H, Stahl M, Rägo L. World Health Organisation (WHO). InBioequivalence Requirements in Various Global Jurisdictions 2017 Dec 6 (pp. 307-331). Cham: Springer International Publishing.
[31] Gilliland-Swetland AJ. Electronic records management. Annu. Rev. Inf. Sci. Technol.. 2005 Jan 1;39(1):219-53.
[32] Khan JA, Shon HK, Nghiem LD. From the laboratory to full-scale applications of forward osmosis: research challenges and opportunities. Current Pollution Reports. 2019 Dec;5(4):337-52.
[33] Sengupta P, Chatterjee B, Tekade RK. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. International journal of pharmaceutics. 2018 May 30;543(1-2):328-44.
[34] Massey AK, Rutledge RL, Antón AI, Swire PP. Identifying and classifying ambiguity for regulatory requirements. In2014 IEEE 22nd international requirements engineering conference (RE) 2014 Aug 25 (pp. 83-92). IEEE.
[35] Chatzoglou PD. Factors affecting completion of the requirements capture stage of projects with different characteristics. Information and Software Technology. 1997 Jan 1;39(9):627-40.
[36] Pharmacopeia US. The United States Pharmacopeia, USP 43-National Formulary, NF 38. Rockville, MD: US Pharmacopeial Convention.
[37] World Health Organization. The international pharmacopoeia. World Health Organization; 2006.
[38] Elder D. ICH Q6A Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. ICH quality guidelines: an implementation guide. 2017 Sep 27:433-66.
[39] Indian Pharmacopoeia Commission. Microbial Contamination in Non-Sterile Products, Chapter 2.2.9. Indian Pharmacopeia. Ghaziabad: IPC.

[40] Guideline IH. Impurities in new drug substances Q3A (R2). InProceedings of the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use, Geneva, Switzerland 2006 Oct 25 (Vol. 25).
[41] Sandle T. Data Integrity and compliance in the pharmaceutical industry: ALCOA to ALCOA+. PDA J Pharm Sci Technol. 2018;72(5):456–468.
[42] PIC/S. PI 041-1: Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments. Geneva: PIC/S; 2021.
[43] Peris-Vicente J, Esteve-Romero J, Carda-Broch S. Validation of analytical methods based on chromatographic techniques: An overview. Analytical separation science. 2015 Dec 7:1757-808.
[44] World Health Organization. WHO good data and record management practices — Annex 4: Data integrity principles. WHO TRS; 2016.
[45] Lopez O. Data Integrity in Pharmaceutical and Medical Devices Regulation Operations: Best Practices Guide to Electronic Records Compliance. Productivity Press; 2016 Nov 3.
[46] European Medicines Agency. Reflection paper on expectations for data integrity (EMA/INS/GCP/53255/2016). London: EMA; 2016.
[47] Richman J. Evidence mapping for regulatory submissions: best practices and templates. Regul Toxicol Pharmacol. 2017;87:174–181.
[48] Kulkarni P, Kothari C. Documentation and data integrity in pharmaceutical industry. InModern Aspects of Pharmaceutical Quality Assurance: Developing & Proposing Application models, SOPs, practical audit systems for Pharma Industry 2024 Mar 12 (pp. 381-403). Singapore: Springer Nature Singapore.
[49] Omoit DF, Otieno GO, Rucha KK. Measuring the extent of compliance to standard operating procedures for documentation of medical records by healthcare workers in Kenya. Journal of Public Health Research. 2020 Jul 3;2:78-86.
[50] Narang A, Desai D. Pharmaceutical product launch: The critical role of regulatory readiness. J Pharm Innov. 2021;16(3):481–493.
[51] Jain SK, Jain RK. Investigations and CAPA: Quality system for continual improvement in pharmaceutical industry. International Journal of Research in Pharmacy and Pharmaceutical Sciences. 2017 Nov 1;2(6):47-54.
[52] Primer PQ. Technical data sheet. Red. 2014 Aug 1;2(4):1.
[53] Yenni GM, Christensen EM, Bledsoe EK, Supp SR, Diaz RM, White EP, Ernest SM. Developing a modern data workflow for regularly updated data. PLoS Biology. 2019 Jan 29;17(1):e3000125.
[54] Боголій О. A TEMPLATE FOR TECHNICAL DESIGN DOCUMENTS TO HELP DISTRIBUTED SOFTWARE DEVELOPMENT TEAMS COLLABORATE BETTER. Економіка та суспільство. 2024 May 27(63).
[55] ADHESIVE CP. Technical data sheet.
[56] Ballard G. Phase scheduling. LCI White Paper. 2000 Apr 27;7:7-9.
[57] Smith ML, Erwin J, Diaferio S. Role & responsibility charting (RACI). InProject Management Forum (PMForum) 2005 (Vol. 5, p. 12).
[58] Patel H, Patel A, Prajapati V, Gajjar A. Preparation and review of chemistry, manufacturing and control (CMC) sections of CTD dossier for marketing authorization. Int J Drug Regul Aff. 2017;5(2):1–12.
[59] Mishra MK, et al. Pharmaceutical preformulation studies in formulation and development of new dosage form: A review. Int J Pharm Sci Rev Res. 2018.
[60] EMA. Guideline on process validation for finished products — information and quality. European Medicines Agency; 2011.
[61] Shukla P, et al. Quality risk management for specifications: practical examples. J Pharm Sci. 2016;105(10):3019–3030.
[62] ICH. Q12 — Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Geneva: ICH; 2019.
[63] Cartwright AC. The Common Technical Document—A Global Format for Registration Files. InInternational pharmaceutical product registration 2016 Apr 19 (pp. 17-29). CRC Press.
[64] Maggetti M. Legitimacy and Accountability of Independent Regulatory Agencies: A Critical Review. Living Reviews in Democracy. 2010 Jan 1;2.
[65] Fiorino M, Barone C, Barone M, Mason M, Bhagat A. Quality Audits in Food Companies and the Examination of Technical Data Sheets.

InQuality Systems in the Food Industry 2019 Jun 6 (pp. 39-45). Cham: Springer International Publishing.

[66] Tiwari JB. Development and Validation of Calculation Data Sheets to Ensure the Accuracy and Security of Pharmaceutical Data Through Qa Procedures (Qaps).

[67] Ramapriyan HK, Peng G, Moroni D, Shie CL. Ensuring and improving information quality for Earth science data and products. D-Lib Magazine. 2017 Jul;23(7/8).

[68] Vennapureddy S. Poster: Vault Clinical Operations Management System (CTMS) Used in Research Organizations for Fast Medicine & Therapies Available to the Public. In2024 IEEE/ACM Conference on Connected Health: Applications, Systems and Engineering Technologies (CHASE) 2024 Jun 19 (pp. 195-197). IEEE.

[69] Bobby CL. The Importance of Safeguarding Functional Independence in External Quality Assurance Decision-Making Activities. InMajor Challenges Facing Higher Education in the Arab World: Quality Assurance and Relevance 2019 Mar 26 (pp. 109-123). Cham: Springer International Publishing.

[70] Knight MM. *Quality Assurance/Quality Improvement Programme* (Doctoral dissertation, National University of Ireland, Maynooth).

[71] Pisano GP. Knowledge, integration, and the locus of learning: An empirical analysis of process development. Strategic management journal. 1994 Dec;15(S1):85-100.

[72] Pisano GP. Knowledge, Integration, and the Locus of Learning: an Empirical Analysis of Process Development. Long Range Planning. 1995;28(4):125-.

[73] Arshad M, Saha S, Sahu SK. DEVELOPMENT OF RACI MATRIX FOR COMPLETE MACHINE LIFECYCLE.

[74] Åbonde D. How to Optimize the Way of Working Within Commissioning.

[75] Reamer, F. G.. (2005). *Documentation in Social Work: Evolving Ethical and Risk-Management Standards. Social Work, 50(4), 325–334.* doi:10.1093/sw/50.4.325

[76] McDowall RD. Data integrity and data governance: practical implementation in regulated laboratories. Royal Society of Chemistry; 2018 Nov 6.

[77] Pérez JR. Maintaining data integrity. Quality Progress. 2017 Mar 1;50(3):14.

[78] Barkow S, Takahashi K. Current expectations and guidance, including data integrity and compliance with CGMP. Center for Drug Evaluation and Research. 2017 Mar 30.

[79] Dolce M, Di Bucci D. Risk management: roles and responsibilities in the decision-making process. Geoethics: ethical challenges and case studies in earth science. Section IV: Communication with the public, officials and the media. 2014 Nov 13.

[80] Andreeva S, Velikanova S, Chernykh O, Kozhushkova N, Samarokova I, Arakcheeva Z. The risk-based thinking in managing documents as assets. Journal of Economic & Management Perspectives. 2017 Jun 1;11(2):829-37.

[81] McDowall RD. Are You Ready for the Latest Data Integrity Guidance? Part 1: Scope, Data Governance, and Paper Records.

[82] McDowall RD, Burgess C. Data Governance, Data Integrity, and Data Quality. Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. 2025 Apr 7:13-33.

[83] Sandle T. Good documentation practices. Journal of validation technology. 2014.

[84] Lorch Z. BEST PRACTICES AND SOURCES OF ERROR: WHAT PROJECT DOCUMENTATIONS REVEAL ABOUT THE SUCCESS OF INFRASTRUCTURE PROJECTS. Образование, научни изследвания и иновации. 2025;3(2):12-6.

[85] Shahbodaghi A, Moghaddasi H, Asadi F, Hosseini A. Documentation errors and deficiencies in medical records: a systematic review. Journal of Health Management. 2024 Apr;26(2):351-68.

[86] Su CF, Chu CM, Yuan YJ, Peng CC, Feng CC, Chao SL, Lin CS. Use of a modified fishbone diagram to analyze diagnostic errors in emergency physicians. Journal of Acute Medicine. 2017 Dec 1;7(4):149.

[87] Ismael A, Okumus I. Design and implementation of an electronic document management system. Mehmet Akif Ersoy Üniversitesi Uygulamalı Bilimler Dergisi. 2017;1(1):9-17.

[88] Rein GL, McCue DL, Slein JA. A case for document management functions on the Web.

Communications of the ACM. 1997 Sep 1;40(9):81-9.

[89] Sprague Jr RH. Electronic document management: Challenges and opportunities for information systems managers. MIS quarterly. 1995 Mar 1:29-49.

[90] Sawant N, Caudhari BP, Redasani VK, Mulla S. Documentation in Pharmaceutical Industry. Asian Journal of Research in Pharmaceutical Sciences. 2025 Jul 10;15(3):315-21.

[91] Sreekanthaswamy N, Anitha S, Singh A, Jayadeva SM, Gupta S, Manjunath TC, Selvakumar P. Digital tools and methods. InEnhancing School Counseling With Technology and Case Studies 2025 (pp. 25-48). IGI Global Scientific Publishing.

[92] Shahbodaghi A, Moghaddasi H, Asadi F, Hosseini A. Documentation errors and deficiencies in medical records: a systematic review. Journal of Health Management. 2024 Apr;26(2):351-68.

[93] Aherne DP, Hunt I, Kourousis KI, Chatzi A. Human factors considerations for critical maintenance tasks and their effect on the transition to digital documentation: an exploratory expert survey.

[94] Pastore L. *Launch Management Process in Automotive. A tool for managing the modern complexity of the Project Development in the phase close to Start of Production. Theoretical base and application to a real case study* (Doctoral dissertation, Politecnico di Torino).

[95] Al Alam SD, Pfahl D, Ruhe G. Release readiness classification: An explorative case study. InProceedings of the 10th ACM/IEEE International Symposium on Empirical Software Engineering and Measurement 2016 Sep 8 (pp. 1-7).

[96] Guiltinan JP. Launch strategy, launch tactics, and demand outcomes. Journal of Product Innovation Management: AN INTERNATIONAL PUBLICATION OF THE PRODUCT DEVELOPMENT & MANAGEMENT ASSOCIATION. 1999 Nov;16(6):509-29.

[97] Haque A, Pant AB. Efforts at COVID-19 vaccine development: challenges and successes. Vaccines. 2020 Dec 6;8(4):739.

[98] Rathee V, Pihwal K, Pawar N, Aamir S, Alam MS, Bahmani K. Indian Pharmaceutical Industries Current Status and Togetherness to Overcome Speed Breakers in Term of Quality Issues to make India as a Global Pharma Destination. Applied Drug Research, Clinical Trials and Regulatory Affairs: Formerly Applied Clinical Research, Clinical Trials and Regulatory Affairs. 2021 Apr 1;8(1):19-31.

[99] Shi A. Reviewing refusal: Lethal injection, the FDA, and the courts. University of Pennsylvania Law Review. 2019 Dec 1;168(1):245-76.

[100] Ardilio A, Warschat J, Spath D. Customized technology readiness: Introducing the application specific technology readiness model. In2012 Proceedings of PICMET'12: Technology Management for Emerging Technologies 2012 Jul 29(pp. 1260-1272). IEEE.